We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
PURPOSE This multicenter phase II study was undertaken to investigate the efficacy and feasibility of gefitinib for patients with advanced non-small-cell lung cancer ( NSCLC ) harboring epidermal growth factor receptor ( EGFR ) mutations without indication for chemotherapy as a result of poor performance status ( PS ) . PATIENTS AND METHODS  Chemotherapy-naïve patients with poor PS ( patients 20 to 74 years of age with Eastern Cooperative Oncology Group PS 3 to 4 , 75 to 79 years of age with PS 2 to 4 , and > or= 80 years of age with PS 1 to 4 ) who had EGFR mutations examined by the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp method were enrolled and received gefitinib ( 250 mg/d ) alone . RESULTS Between February 2006 and May 2007 , 30 patients with NSCLC and poor PS , including 22 patients with PS 3 to 4 , were enrolled . The overall response rate was 66 % ( 90 % CI , 51 % to 80 % ) , and the disease control rate was 90 % . PS improvement rate was 79 % ( P < .00005 ) ; in particular , 68 % of the 22 patients improved from > or= PS 3 at baseline to < or= PS 1 . The median progression-free survival , median survival time , and 1-year survival rate were 6.5 months , 17.8 months , and 63 % , respectively . No treatment-related deaths were observed . CONCLUSION This is the first report indicating that EGFR mutation-positive patients with extremely poor PS benefit from first-line gefitinib . Because there previously has been no st and ard treatment for these patients with short life expectancy other than best supportive care , examination of EGFR mutations as a biomarker is recommended in this patient population
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV